



Contacts:

David Waldman or Justyna Gudaszevska
Crescendo Communications Europe Sp. z.o.o
Email: mmd@crescendo-ir.com
Tel: (+48) 693 354 580

**Milestone Medical, Inc. Provides Update Regarding
Distribution and Product Platform Strategy for Epidural Instrument in the Middle East
and North Africa (MENA) regions**

LIVINGSTON, NJ, March 3, 2017 -- Milestone Medical, Inc. (WAR: MMD) today announced it has begun its clinical rollout for the epidural instrument in the Middle East and North Africa (MENA) regions, by initiating clinical evaluations at key hospitals in the United Arab Emirates and in Lebanon. Given the extensive published clinical data supporting successful epidural catheter placement in patients with complex co-morbidities, clinicians and key opinion leaders in these territories have expressed further interest in broadening the technique scope into challenging thoracic epidural procedures, as well as extending its use into pediatric cases.

Milestone Medical is also continuing its collaboration with key opinion leaders in Italy with a focus on expanding its clinical utilization at key hospitals in Rome, Florence, Naples and Pesaro, which resulted in additional scientific data accepted for presentation at the upcoming meeting of the European Society for Anesthesiology to be held in Geneva, Switzerland from June 3-5, 2017. Euroanaesthesia is Europe's largest annual event showcasing the latest and the most relevant knowledge with medical experts active in the fields of anesthesia, perioperative medicine, intensive care, emergency medicine and pain treatment.

Milestone had a successful showing at Arab Health 2017, which is the largest gathering of healthcare and trade professionals in the MENA region and the 2nd largest healthcare exhibition and congress in the world. Numerous distributors from the MENA and the Asia/Pacific regions expressed the interest in distribution of Milestone's epidural and intra-articular injection instruments.

Milestone's DPS Dynamic Pressure Sensing Technology™ continues to lead the way as a superior alternative to the more expensive technologies such as ultrasound and fluoroscopy that are being used to identify the epidural space. A recent clinical publication in the Journal Regional Anesthesia and Pain Medicine independently confirmed the lower failure rates of pressure-based epidural waveform analysis. Milestone's CompuFlo™ Epidural Instrument is the first commercial product to come to market with waveform-generating dynamic pressure sensing capabilities.

Leonard Osser, Chief Executive Officer of Milestone Medical, stated, "We are further encouraged by the interest in our epidural instruments by medical practitioners in Europe and the MENA regions, including the use of our instrument for patients with complex co-morbidities, as well as prospects of intended use into pediatric patients."

About Milestone Medical Inc.

Milestone Medical, Inc. has developed epidural and intra-articular drug delivery systems based on a patented, painless, computer-controlled injection and drug delivery technology originally developed by Milestone Scientific, Inc. Development of both the epidural and intra-articular instruments is now complete and the Company is currently pursuing regulatory approval for both instruments in the U.S.

Milestone Medical received CE Mark approval to sell and market its intra-articular and epidural instruments across European Union. For more information please visit www.medicalmilestone.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, receipt of regulatory approvals, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2015. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.